136 related articles for article (PubMed ID: 31810002)
1. Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma.
Liu X; Chen J; Li W; Hang C; Dai Y
Transl Oncol; 2020 Jan; 13(1):70-78. PubMed ID: 31810002
[TBL] [Abstract][Full Text] [Related]
2. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
[TBL] [Abstract][Full Text] [Related]
3. Ursolic acid attenuates temozolomide resistance in glioblastoma cells by downregulating O(6)-methylguanine-DNA methyltransferase (MGMT) expression.
Zhu Z; Du S; Ding F; Guo S; Ying G; Yan Z
Am J Transl Res; 2016; 8(7):3299-308. PubMed ID: 27508051
[TBL] [Abstract][Full Text] [Related]
4. Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Nitta RT; Bolin S; Luo E; Solow-Codero DE; Samghabadi P; Purzner T; Aujla PS; Nwagbo G; Cho YJ; Li G
Oncogene; 2019 Oct; 38(42):6867-6879. PubMed ID: 31406250
[TBL] [Abstract][Full Text] [Related]
5. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
7. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
[TBL] [Abstract][Full Text] [Related]
8. Differentiated embryonic chondrocyte-expressed gene 1 promotes temozolomide resistance by modulating the SP1-MGMT axis in glioblastoma.
Lv W; Li Q; Jia B; He Y; Ru Y; Guo Q; Li X; Lin W
Am J Transl Res; 2021; 13(4):2331-2349. PubMed ID: 34017393
[TBL] [Abstract][Full Text] [Related]
9. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Harder BG; Peng S; Sereduk CP; Sodoma AM; Kitange GJ; Loftus JC; Sarkaria JN; Tran NL
Mol Med; 2019 Nov; 25(1):49. PubMed ID: 31726966
[TBL] [Abstract][Full Text] [Related]
11. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
Yang B; Ma YB; Chu SH
Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
[TBL] [Abstract][Full Text] [Related]
12. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
Ferrer-Font L; Villamañan L; Arias-Ramos N; Vilardell J; Plana M; Ruzzene M; Pinna LA; Itarte E; Arús C; Candiota AP
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208677
[TBL] [Abstract][Full Text] [Related]
13. BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.
Li M; Liang RF; Wang X; Mao Q; Liu YH
Oncol Lett; 2017 Dec; 14(6):6597-6603. PubMed ID: 29151909
[TBL] [Abstract][Full Text] [Related]
14. Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Murphy SF; Varghese RT; Lamouille S; Guo S; Pridham KJ; Kanabur P; Osimani AM; Sharma S; Jourdan J; Rodgers CM; Simonds GR; Gourdie RG; Sheng Z
Cancer Res; 2016 Jan; 76(1):139-49. PubMed ID: 26542214
[TBL] [Abstract][Full Text] [Related]
15. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
16. Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.
Ciechomska IA; Marciniak MP; Jackl J; Kaminska B
Front Pharmacol; 2018; 9():1271. PubMed ID: 30450051
[TBL] [Abstract][Full Text] [Related]
17. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
18. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
[TBL] [Abstract][Full Text] [Related]
19. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
